Adverse event 1 (0.8%) Investigator decision 1 (0.8%) Protocol violation 1 (0.8%) Lost to follow-up 2 (1.7%) Administrative 1 (0.8%) Loss of glucose control 2 (1.7%)Withdrew 14 (10.8%) Withdrawal of consent 5 (3.8%) Adverse event 3 (2.3%) Investigator decision 1 (0.8%) Protocol violation 0 Lost to follow-up 2 (1.5%) Administrative 2 (1.5%) Loss of glucose control 1 (0.8%) Demographics and baseline characteristics (52-week evaluable, n= 116) Sex (%)   Male 67 (58%) Female 49 (42%) Race/ethnicity (%) Caucasian 41 (35%) Black 12 (10%) Hispanic 30 (26%) Asian 31 (27%) Native American 2 (2%)   Other 0 Age (years) 53 ± 11 Weight (kg) 88 ± 21 Body mass index (kg/m2)3 2 ± 5 HbA 1c (%) 8.5 ± 1.1 Fasting glucose (mmol/l) 9.0 ± 2.5 Duration of diabetes (years) 6±5Withdrew 15 (13.0%) Withdrawal of consent 5 (4.3%) A d v e r s ee v e n t 8( 7 . 0 % ) Investigator decision 0 Protocol violation 0 Lost to follow-up 1 (0.9%) Administrative 0 Loss of glucose control 1 (0.9%)